Dose rate in brachytherapy using after-loading machine: Pulsed or high-dose rate?

Hannoun-Lévi, J.-M.; Peiffert, D.

doi:10.1016/j.canrad.2014.07.156

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In October 2016, consecutive locoregional brachytherapy using an after-loading technique [20, 21] showed also fast progression of the hepatic metastases. Similarly, everolimus, an mTOR-inhibitor, was experimentally initiated despite a high Ki 67 > 50% [22, 23].…”

Section: Case Reportmentioning

confidence: 99%

Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab

Stüven

Wiedenmann

2019

Oncotarget

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumors, which can be histologically separated by primary location, proliferation rate and differentiation of tumor cells. The therapeutic options and outcome depend on grading, staging and resectability of the tumor. Established treatment options of neuroendocrine tumors (NET) and carcinomas (NEC) are based especially on surgery, tumor specific medical treatments, peptide guided radioreceptor therapy (PRRT) and locoregional therapies. We report about a patient diagnosed with a pancreatic, non-functional NET/NEC G2/3 with a proliferation rate of 20% at initial immunohistochemical diagnosis. During the course of the disease, the proliferation rate increased up to more than 50% over a period of 5 years. Due to loss of response to established therapies (i.e. systemic chemotherapy, targeted therapy and brachytherapy), an off-label immunotherapy with the PD-1 antibody pembrolizumab was initiated based on a 30% PD-L1 expression in tumor cells. This report is the first demonstrating a partial remission of a pancreatic NEN using pembrolizumab monotherapy with a hepatic tumor volume reduction of at least 66%, combined with an improvement of the Karnofsky score rising from 60% to 100%. This case offers insight into the potential role of immunotherapy in a subgroup of neuroendocrine neoplasms.

show abstract

Section: Case Reportmentioning

confidence: 99%

Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab

Stüven

Wiedenmann

2019

Oncotarget

View full text Add to dashboard Cite

show abstract

“…53 Since 2014, in France, it is impossible to use LDR brachytherapy with Iridium-192 wires due to the end of its commercialization, and so after-loading machines (curietherapy systems) are the alternative, offering two treatment possibilities based on the dose rate: pulsed-dose rate (PDR) and high-dose rate (HDR). [58][59][60][61] To keep performing interstitial brachytherapy, the PDR was the only option, but in the case of skin and even more the nasal planum, the thickness is not enough to implantation, and so HDR brachytherapy was developed to irradiate superficial lesions in a fast treatment modality (dose rate over 12 Gy/h). 56,58 In HDR brachytherapy vectors are responsible for delivering a radioisotope, from a remote radioisotope delivery unit computer-controlled, directly to the neoplastic tissue, which allows a sparing effect on the surrounding normal tissues and none dissipation of radiation to the room and, mostly, to the technicians, although a proper shielded room is not dismissed.…”

Section: High-dose Rate Brachytherapymentioning

confidence: 99%

“…Brachytherapy is a method of delivering radiation at a short distance through an after-loading machine (curietherapy system) that offers two treatment possibilities based on the dose rate: pulsed-dose rate and high-dose rate (HDR). 22–25…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors for cats with squamous cell carcinoma of the nasal planum following high-dose rate brachytherapy

Lino

Lanoré²,

Lajoinie³

et al. 2019

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Objectives The aim of the study was to investigate retrospectively the prognostic impact of variables such as sex, neuter status, breed, age, number of lesions, location and size of the tumour, tumour extension beyond the nasal planum, ulceration and lymph node status, among others, in a population of cats treated with high-dose rate brachytherapy. Methods This study reviews the outcome of 58 cats with cytologically and/or histologically confirmed squamous cell carcinoma of the nasal planum, treated at the Clinic Alliance (Bordeaux, France) with high-dose rate brachytherapy from 2010–2016. The total radiation dose delivered was 30 Gy, administered in two different schedules: five fractions of 6 Gy for a period of 4 days (Tuesday–Friday) or four fractions of 7.5 Gy for a period of 3 days (Tuesday– Thursday). Data were collected from cats’ clinical records. Results Complete response was achieved in 72% (n = 36) of the cats, partial response in 24% (n = 13) and 2% (n = 1) did not respond. Median progression-free survival and overall survival times were 316 and 835 days, respectively. Conclusions and relevance Results indicated that sex ( P = 0.045), extension of the tumour from the nasal planum to the upper lip ( P = 0.015), tumour size ( P = 0.015; P = 0.001), the existence of a previous treatment ( P = 0.043) and the tumour response to high-dose rate brachytherapy ( P = 0.038; P <0.001) are prognostic factors for cats with squamous cell carcinoma of the nasal planum following high-dose rate brachytherapy.

show abstract

High-dose-rate brachytherapy for facial skin cancer: Outcome and toxicity assessment for 71 cases

Renard

Salleron

et al. 2021

Brachytherapy

View full text Add to dashboard Cite

Dose rate in brachytherapy using after-loading machine: Pulsed or high-dose rate?

Cited by 6 publications

References 20 publications

Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab

Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab

Prognostic factors for cats with squamous cell carcinoma of the nasal planum following high-dose rate brachytherapy

High-dose-rate brachytherapy for facial skin cancer: Outcome and toxicity assessment for 71 cases

Contact Info

Product

Resources

About